CNN’s report on Brazilian customs officers pulling weight-loss injections out of boot soles, shampoo bottles and massage gel containers has been syndicated across a dozen US outlets this weekend, every version framed as a smuggling and public-health story. It is a good story. It is also, read as a business document, something sharper than any of those versions said: the contraband is concentrated almost perfectly on one side of a patent boundary, and the boundary belongs to Eli Lilly.
Semaglutide, the molecule behind Novo Nordisk’s Ozempic and Wegovy, came off patent in Brazil in March. Tirzepatide, the molecule behind Lilly’s Mounjaro, did not. Guess which one is being hidden in car panels.
Two Molecules, Two Very Different Prices
Semaglutide lost its Brazilian protection in March, freeing domestic firms to make their own versions for the first time. They moved immediately. EMS won approval in May for its own pen, sold as Ozivy, which began reaching pharmacies this month, and Hypera filed for its rival Semavy on June 24. More sellers usually mean lower prices, and analysts expect those domestic pens to push treatment costs down and widen access for patients who cannot afford the imported brands. IQVIA has been mapping the same shift across every market where exclusivity lapses this year.
Tirzepatide has no such opening. It remains under patent in Brazil, and Mounjaro accordingly costs upwards of 1,400 reais, about $280. In Paraguay, locally manufactured tirzepatide sells for roughly 340 reais, about $68. That is a $212 gap on the same molecule, separated by a land border Brazilians cross routinely.
The demand behind that arbitrage is not marginal. Online orders linked to GLP-1 medicines in Brazil rose 149.3 percent in the first half of 2026, from 547,249 in the previous six months to more than 1.36 million, worth over $460 million. Brazilian authorities have logged 83 deaths under investigation and more than 3,600 complications tied to these drugs since 2018.
The Enforcement Framing Is a Category Error
Novo’s public position is that GLP-1 popularity has expanded the market for compounded, counterfeit or illegally imported product sold outside regulated channels. That is accurate as far as it goes, and it is also doing a lot of work.
Paraguayan tirzepatide manufactured under a different national patent regime is not counterfeit. It is a legitimate product that happens to be legal there and unaffordable here, and calling the whole category counterfeit blurs a genuine safety problem, which is unsupervised injectable use, with a commercial problem, which is that Lilly’s Brazilian price is four times the price available ninety minutes away.
Those two problems have different fixes. Customs seizures address the first badly and the second not at all. As long as a $212 spread exists on a drug patients are already taking, someone will move product across that border, and the more successful the interdiction, the higher the margin for whoever gets through.
This is the same tension we saw when Novo sued Hims and Hers over copycat Wegovy in the US: litigation aimed at the symptom while the price gap that creates the symptom stays untouched. Novo eventually moved on price instead, which is the part of that episode worth remembering.
Where We Come Down
Lilly is exposed here in a way its earnings calls have not acknowledged, and the exposure is self-inflicted.
The company is defending a premium price in a middle-income market on the strength of a patent, while a neighbouring country manufactures the same molecule at a quarter of the cost and Brazilian demand grows 149 percent in six months. That is not a stable structure. It is a subsidy to smugglers, paid for in Lilly’s forgone volume and in the safety of patients who end up injecting product of unknown provenance because the legal version costs $280.
Novo, having lost its Brazilian patent, is being forced into the answer Lilly still has the option to choose voluntarily: compete on price in emerging markets rather than hold a US-anchored number until exclusivity runs out. Novo already guides to sales and profit falling 5 to 13 percent this year, partly because exclusivity is lapsing in Brazil, China and Canada. Lilly’s Mounjaro growth has been extraordinary, up 125 percent year over year in the first quarter, which is precisely why the Brazil decision matters now rather than at expiry.
Lilly should cut the Brazilian price of Mounjaro, and it should do it before the patent forces the issue. Not for reputational reasons. Because a company earning $280 on units it does not sell is losing to a $68 competitor it refuses to name.
The metric to watch is not seizure counts. It is whether Ozivy and the generics behind it drag Brazilian semaglutide pricing down far enough that patients switch molecules entirely. If they do, Lilly’s patent stops being an asset in that market and starts being the reason its drug is the one in the boot.